MicroRNA Expression in Circulating Microvesicles Predicts Cardiovascular Events in Patients With Coronary Artery Disease

Author:

Jansen Felix1,Yang Xiaoyan2,Proebsting Sebastian1,Hoelscher Marion1,Przybilla David1,Baumann Katharina1,Schmitz Theresa1,Dolf Andreas3,Endl Elmar3,Franklin Bernardo S.4,Sinning Jan‐Malte1,Vasa‐Nicotera Mariuca1,Nickenig Georg1,Werner Nikos1

Affiliation:

1. Department of Internal Medicine II, Rheinische Friedrich‐Wilhelms University, Bonn, Germany

2. Feinberg Cardiovascular Research Institute, Northwestern University School of Medicine, Chicago, IL

3. Institute of Molecular Medicine, Rheinische Friedrich‐Wilhelms University, Bonn, Germany

4. Institute of Innate Immunity, Rheinische Friedrich‐Wilhelms University, Bonn, Germany

Abstract

Background Circulating micro RNA s (mi RNA s) are differentially regulated and selectively packaged in microvesicles (MVs). We evaluated whether circulating vascular and endothelial mi RNA s in patients with stable coronary artery disease have prognostic value for the occurrence of cardiovascular ( CV ) events. Methods and Results Ten mi RNA s involved in the regulation of vascular performance—miR‐126, miR‐222, miR‐let7d, miR‐21, miR‐20a, miR‐27a, miR‐92a, miR‐17, miR‐130, and miR‐199a—were quantified in plasma and circulating MV s by reverse transcription polymerase chain reaction in 181 patients with stable coronary artery disease. The median duration of follow‐up for major adverse CV event–free survival was 6.1 years (range: 6.0–6.4 years). Events occurred in 55 patients (31.3%). There was no significant association between CV events and plasma level of the selected mi RNA s. In contrast, increased expression of miR‐126 and miR‐199a in circulating MV s was significantly associated with a lower major adverse CV event rate. In univariate analysis, above‐median levels of miR‐126 in circulating MV s were predictors of major adverse CV event–free survival (hazard ratio: 0.485 [95% CIAUTHOR : Is 95% CI correct?: 0.278 to 0.846]; P =0.007) and percutaneous coronary interventions (hazard ratio: 0.458 [95% CI : 0.222 to 0.945]; P =0.03). Likewise, an increased level of miR‐199a in circulating MV s was associated with a reduced risk of major adverse CV events (hazard ratio: 0.518 [95% CI : 0.299 to 0.898]; P =0.01) and revascularization (hazard ratio: 0.439 [95% CI : 0.232 to 0.832]; P =0.01) in univariate analysis. mi RNA expression analysis in plasma compartments revealed that miR‐126 and miR‐199a are present mainly in circulating MV s. MV ‐sorting experiments showed that endothelial cells and platelets were found to be the major cell sources of MV s containing miR‐126 and miR‐199a, respectively. Conclusion MV s containing miR‐126 and miR‐199a but not freely circulating mi RNA expression predict the occurrence of CV events in patients with stable coronary artery disease.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3